In vitro susceptibility of mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-Lactamase inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 7010-7014

  Horita, Yasuhiro ^a   Maeda, Shinji ^a   Kazumi, Yuko ^a   Doi, Norio ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN; AMPICILLIN; AVIBACTAM; BETA LACTAMASE INHIBITOR; BIAPENEM; CARBAPENEM; CLARITHROMYCIN; CLAVULANIC ACID; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; RIFAMPICIN; TEBIPENEM; CARBAPENEM DERIVATIVE; DRUG COMBINATION; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD; DRUG POTENCY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; DRUG COMBINATION; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; BETA-LACTAMASE INHIBITORS; CARBAPENEMS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84908610389     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03539-14     Document Type: Article

References (33)

1. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, Hoffner SE. 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136:420-425. http://dx.doi.org/10.1378/chest.08-2427.
2. Velayati AA, Farnia P, Masjedi MR. 2013. The totally drug resistant tuberculosis (TDR-TB). Int. J. Clin. Exp. Med. 6:307-309.
3. World Health Organization. 2013. Global tuberculosis report 2013. WHO, Geneva, Switzerland.
4. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. 1991. Amoxicillinclavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 99:1025-1026. http://dx.doi.org/10.1378/chest.99.4.1025.
5. Payen MC, De Wit S, Martin C, Sergysels R, Muylle I, Van Laethem Y, Clumeck N. 2012. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 16:558-560. http://dx.doi.org/10.5588/ijtld.11.0414.
6. Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL. 2013. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J. Infect. Dis. 207:1352-1358. http://dx.doi.org/10.1093/infdis/jis460.
7. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, Spanevello A, Migliori GB. 2013. Efficacy and safety of meropenem-clavulanate added to linezolidcontaining regimens in the treatment of MDR-/XDR-TB. Eur. Respir. J. 41: 1386-1392. http://dx.doi.org/10.1183/09031936.00124312.
8. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. 2005. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob. Agents Chemother. 49:2816-2821. http://dx.doi.org/10.1128/AAC.49.7.2816-2821.2005.
9. Sloan DJ, Davies GR, Khoo SH. 2013. New drugs and treatment regimens. Curr. Resp. Med. Rev. 9:200-210. http://dx.doi.org/10.2174/1573398X113099990017.
10. Gonzalo X, Drobniewski F. 2013. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J. Antimicrob. Chemother. 68:366-369. http://dx.doi.org/10.1093/jac/dks395.
11. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE, III, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 323:1215-1218. http://dx.doi.org/10.1126/science.1167498.
12. Yamane N, Ichiyama S, Kawahara S, Iinuma Y, Saitoh H, Shimojima M, Udagawa H, Nakasone I. 1999. Multicenter evaluation of broth microdilution test, BrothMIC MTB, to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for Mycobacterium tuberculosis- evaluation of interlaboratory precision and interpretive compatibility with agar proportion method. Rinsho Byori 47:754-766.
13. Gumbo T. 2010. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob. Agents Chemother. 54:1484-1491. http://dx.doi.org/10.1128/AAC.01474-09.
14. EUCAST. 2013. EUCAST clinical breakpoints table, version 3.1-2013-02-11 EUCAST, Växjö, Sweden.
15. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. http://dx.doi.org/10.1038/nm0696-662.
16. Wada T, Maeda S, Tamaru A, Imai S, Hase A, Kobayashi K. 2004. Dual-probe assay for rapid detection of drug-resistant Mycobacterium tuberculosis by real-time PCR. J. Clin. Microbiol. 42:5277-5285. http://dx.doi.org/10.1128/JCM.42.11.5277-5285.2004.
17. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM. 1993. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31:406-409.
18. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagoz S, Rosenberg E, Hadley WK, Nikaido H. 1995. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39:2620-2624. http://dx.doi.org/10.1128/AAC .39.12.2620.
19. Abate G, Miorner H. 1998. Susceptibility of multidrug-resistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol. J. Antimicrob. Chemother. 42:735-740. http://dx.doi.org/10.1093/jac/42.6.735.
20. Solapure S, Dinesh N, Shandil R, Ramachandran V, Sharma S, Bhattacharjee D, Ganguly S, Reddy J, Ahuja V, Panduga V, Parab M, Vishwas KG, Kumar N, Balganesh M, Balasubramanian V. 2013. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:2506-2510. http://dx.doi.org/10.1128/AAC.00023-13.
21. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. 2004. Augmentin (amoxicillin/clavulanate) in the treatment of communityacquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl 1):i3-i20. http://dx.doi.org/10.1093/jac/dkh050.
22. Ball AP, Geddes AM, Davey PG, Farrell ID, Brookes GR. 1980. Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study. Lancet i:620-623.
23. Cordillot M, Dubee V, Triboulet S, Dubost L, Marie A, Hugonnet JE, Arthur M, Mainardi JL. 2013. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob. Agents Chemother. 57:5940-5945. http://dx.doi.org/10.1128/AAC.01663-13.
24. Lavollay M, Arthur M, Fourgeaud M, Dubost L, Marie A, Veziris N, Blanot D, Gutmann L, Mainardi JL. 2008. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J. Bacteriol. 190:4360-4366. http://dx.doi.org/10.1128/JB.00239-08.
25. Dubee V, Triboulet S, Mainardi JL, Etheve-Quelquejeu M, Gutmann L, Marie A, Dubost L, Hugonnet JE, Arthur M. 2012. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt(1) by carbapenems and cephalosporins. Antimicrob. Agents Chemother. 56:4189-4195. http://dx.doi.org/10.1128/AAC.00665-12.
26. Hugonnet JE, Blanchard JS. 2007. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46: 11998-12004. http://dx.doi.org/10.1021/bi701506h.
27. Hazra S, Xu H, Blanchard JS. 2014. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry 53:3671-3678. http://dx.doi.org/10.1021/bi500339j.
28. Kijima K, Morita J, Suzuki K, Aoki M, Kato K, Hayashi H, Shibasaki S, Kurosawa T. 2009. Pharmacokinetics of tebipenem pivoxil, a novel oral carbapenem antibiotic, in experimental animals. Jpn. J. Antibiot. 62:214-240.
29. Mori H, Mizutani T. 2007. In vitro activation of valproate glucuronidation by carbapenem antibiotics. J. Health Sci. 53:302-310. http://dx.doi.org/10.1248/jhs.53.302.
30. Baba S, Yamanaka N, Suzuki K, Furukawa M, Furuya N, Ubukata K, Totsuka K. 2009. Clinical efficacy, safety and PK-PD analysis of tebipenem pivoxil in a phase II clinical trial in otolaryngological infections. Jpn. J. Antibiot. 62:155-177.
31. Nakashima M, Morita J, Aizawa K. 2009. Pharmacokinetics and safety of tebipenem pivoxil fine granules, an oral carbapenem antibiotic, in healthy male volunteers. Jpn. J. Chemother. 57:90-94.
32. Nakashima M, Morita J, Aizawa K. 2009. Pharmacokinetics and safety of oral carbapenem antibiotic tebipenem pivoxil tablets in healthy male volunteers. Jpn. J. Chemother. 57:82-89.
33. Sugano T, Yoshida T, Yamada K, Shimizu A, Morita J, Kijima K, Maebashi K, Shibasaki S. 2009. Antimicrobial activity of tebipenem pivoxil against Streptococcus pneumoniae and Haemophilus influenzae, and its pharmacokinetic-pharmacodynamic profile in mice. Jpn. J. Chemother. 57:38-48.